Acutaas Chemicals Ltd (ACUTAAS) — shareholding pattern, promoter holding, financials and share price

About Acutaas Chemicals Ltd (ACUTAAS)

Acutaas Chemicals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ACUTAAS and on the BSE under scrip code 543349. Its ISIN is INE00FF01025.

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals. [1]

Acutaas Chemicals Limited specializes in manufacturing pharmaceutical intermediates and diversified chemicals, focusing on expanding into battery and semiconductor chemicals.

The company has reported a robust financial performance, with a 43% YoY increase in revenue and a 133.7% increase in PAT in Q3 FY26, highlighting its strong operational leverage and cost efficiencies.

Listed peers in Pharmaceuticals: Wockhardt Ltd, Sai Life Sciences Ltd, Neuland Laboratories Ltd, Rubicon Research Ltd, Piramal Pharma Ltd, Granules India Ltd.

Valuation & Returns

10 Jul 2026

At ₹3,393.95 a share on 10 Jul 2026, Acutaas Chemicals Ltd (ACUTAAS) was valued at a price-to-earnings ratio of 77.97x against an industry P/E of 36.41x and a price-to-book of 21.22x on a book value of ₹159.96 per share as of Mar 2025. Solomo computes return on equity of 27.21% and return on capital employed of 36.75% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
77.97x
Industry P/E
36.41x
P/B
21.22x
EPS (TTM)
₹43.53
Book value / share
₹159.96
ROE
27.21%
ROCE
36.75%
ROA
23%
Debt / equity
0.01x
Dividend yield
0.04%
EBITDA margin
38.97%
52-week range
₹1,124.45 – ₹3,735

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Acutaas Chemicals Ltd (ACUTAAS) reported revenue of ₹1,339 crore, net profit of ₹356 crore and earnings per share of ₹43.51. That compares with revenue of ₹1,007 crore and net profit of ₹160 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹433 crore and net profit ₹134 crore (consolidated).

Consolidated annual results for Acutaas Chemicals Ltd (ACUTAAS), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)5206177171,0071,339
Net profit (₹ cr)728349160356
EPS (₹)9.8711.435.819.3843.51
Compound annual growth for Acutaas Chemicals Ltd (ACUTAAS). Stock price CAGR is price return and excludes dividends.
Measure5Y3Y1Y
Sales growth32.80%23.92%40.34%
Profit growth42.17%30.40%229.34%
Stock price CAGR-82%190%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 32.66% of Acutaas Chemicals Ltd (ACUTAAS) (unchanged from the previous quarter), foreign institutional investors (FII) hold 21.61% and domestic institutional investors (DII) hold 19.56%. Market capitalisation was ₹27,787 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2021.

Largest disclosed public shareholders in Jun 2026: Government Pension Fund Global 3.54%, Kotak Mahindra Trustee Co Ltd A/C Kotak Multicap Fund 3.53%, Dhwani Girishkumar Chovatia 3.35%, Sbi Healthcare Opportunities Fund 2.35%, Axis Max Life Insurance Limited A/C - Ulif01311/02/08lifehighgr104 - High Growth Fund 2.19%, Vanaja Sundar Iyer 1.14%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202632.66%-21.61%19.56%67.34%
Mar 202632.66%-19.48%19.6%67.34%
Dec 202532.66%-16.67%21.7%67.34%
Sep 202532.66%-16.85%22.59%67.34%
Jun 202532.66%-16.94%22.38%67.34%
Mar 202535.96%-16.48%18.31%64.04%
Dec 202435.96%-15.52%20.24%64.04%
Sep 202435.97%-13.87%19.93%64.03%
Every quarter since Sep 2021 Filing data, not investment advice.